FDA approves a biosimilar drug for Roche's heavy breast cancer treatment herselstin
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, it has been reported that the United States hasThe FDA(http://has approved a biosimilar drug from Roche's heavy breast cancer treatmentdrug(http://herceptin (quto-bee monoantigen)the hersothin biosimilar, called o
ntruzant, is sold by Mercado and developed by Samsung Bioepis(http://, a joint venture between Samsung Biologics and Periscope, with sales of CHF 7.01 billion in 2017, is one of the world's most successful antibody drugs and has been a mainstay of Roche's profits for many yearsHeseltine and other complex structural drugs called biologics are bioactive agents made from biotechnology, which allows them to replicate with precision, so their similar versions of the drug are called biosimilars, rather than the usual generics of the genericspharmaceutical(http://."Samsung Bioepis' o
ntruzant has been approved in Europe as the first Herceptin biosimilar, also in partnership with Samsung Bioepis and Mercadohowever, in the U.Smarket biosimilar drugs to market resistance is greater, the current FDA-approved biosimilar sino is still in thepatent(http://litigation disputes, only a few can reach a settlement with the patent drug companyOn July 7, Sansin Pharmaceuticals announced a cooperation agreement with Samsung Bioepis to conduct clinical research and development and commercialization of the(http://of multiple biosimilar
s of Samsung Bioepis in the Chinese mainland (excluding Hong Kong, Macau and Taiwan)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
